Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
Harbin, CN
Harbin Gloria Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical enterprise primarily focused on the research, development, manufacturing, and commercialization of various medicinal products within the People's Republic of China. The company's comprehensive portfolio addresses a broad spectrum of therapeutic areas, including cardiac and cerebrovascular health, skeletal muscle system support, and urinary tract conditions. It also provides vitamins and minerals, as well as medications for oncology, endocrine disorders, anti-infective treatments, respiratory ailments, antihistamine purposes, and peptic concerns, among other pharmaceutical goods. Established in 2000, the firm's headquarters are located in Harbin, also situated in the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00% | -4.52% | -18.23% | -14.94% | -8.36% | -3.58% | -3.58% | +32.74% | +9.63% | -52.96% | +6.65% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-12.5% Q1'26: -2.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+70.0% ★ Q1'26: +59.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+17.5% Q1'26: +12.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.3% ★ Q1'26: +20.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+26.2% ★ Q1'26: +26.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-3.1% ★ Q1'26: -1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.18× ★ Q1'26: 0.05× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.48B
est: 4.06B (+35.1%)
|
2.44B
est: 2.33B (+4.7%)
|
2.14B
est: 3.65B (-41.5%)
|
3.65B
3.65B – 3.65B
+0.0% YoY
|
4.06B
4.06B – 4.06B
+11.2% YoY
|
2.33B
2.33B – 2.33B
-42.5% YoY
|
2.36B
2.36B – 2.36B
+1.4% YoY
|
2.46B
2.46B – 2.46B
+4.2% YoY
|
2.66B
2.66B – 2.66B
+8.0% YoY
|
| EBITDA |
519.52M
est: 529.74M (-1.9%)
|
397.29M
est: 278.12M (+42.9%)
|
502.89M
est: 435.45M (+15.5%)
|
435.45M
435.45M – 435.45M
+0.0% YoY
|
484.02M
484.02M – 484.02M
+11.2% YoY
|
278.17M
278.17M – 278.17M
-42.5% YoY
|
282.11M
282.11M – 282.11M
+1.4% YoY
|
294.04M
294.04M – 294.04M
+4.2% YoY
|
317.55M
317.55M – 317.55M
+8.0% YoY
|
| EBIT |
335.24M
est: 349.99M (-4.2%)
|
293.72M
est: 180.04M (+63.1%)
|
412.10M
est: 281.89M (+46.2%)
|
281.89M
281.89M – 281.89M
+0.0% YoY
|
313.33M
313.33M – 313.33M
+11.2% YoY
|
180.07M
180.07M – 180.07M
-42.5% YoY
|
182.62M
182.62M – 182.62M
+1.4% YoY
|
190.35M
190.35M – 190.35M
+4.2% YoY
|
205.56M
205.56M – 205.56M
+8.0% YoY
|
| Net Income |
125.89M
|
232.76M
|
376.91M
est: 920.89M (-59.1%)
|
920.89M
920.89M – 920.89M
+0.0% YoY
|
1.05B
1.05B – 1.05B
+14.3% YoY
|
197.33M
197.33M – 197.33M
-81.3% YoY
|
241.18M
241.18M – 241.18M
+22.2% YoY
|
285.04M
285.04M – 285.04M
+18.2% YoY
|
306.96M
306.96M – 306.96M
+7.7% YoY
|
| SGA |
3.30B
est: 2.32B (+42.0%)
|
959.35M
est: 1.07B (-10.4%)
|
612.94M
est: 1.68B (-63.4%)
|
1.68B
1.68B – 1.68B
+0.0% YoY
|
1.86B
1.86B – 1.86B
+11.2% YoY
|
1.07B
1.07B – 1.07B
-42.5% YoY
|
1.09B
1.09B – 1.09B
+1.4% YoY
|
1.13B
1.13B – 1.13B
+4.2% YoY
|
1.22B
1.22B – 1.22B
+8.0% YoY
|
| EPS |
0.06
|
0.11
|
0.17
est: 0.42 (-59.5%)
|
0.42
0.42 – 0.42
+0.0% YoY
|
0.48
0.48 – 0.48
+14.3% YoY
|
0.09
0.09 – 0.09
-81.3% YoY
|
0.11
0.11 – 0.11
+22.2% YoY
|
0.13
0.13 – 0.13
+18.2% YoY
|
0.14
0.14 – 0.14
+7.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.89% | 628.1K | 0.95% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 149.3K | 0.65% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 12.5K | 0.44% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 137.2K | 0.39% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 101.6K | 0.29% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 64.2K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kang Zhou | Deputy GM & Non-Independent Director | — | male |
| Leifeng Guo | GM, Chief Financial Officer & Director | — | male |
| Runbao Li | Deputy General Manager | — | male |
| Xiaohang Wang | Deputy General Manager | — | male |
| Xiaojing Zhou | Accounting Supervisor | — | female |
| Yueyin Liu | Deputy GM, Non-Independent Director & Secretary of the Board | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002437.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
